NovaBridge Biosciences (FRA:0VY) Short Percentage of Float


FRA:0VY NovaBridge Biosciences FRA:0VY
24 GF Score
Price €1.84
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is NovaBridge Biosciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:0VY vs HUMA, DTIL, ORMP: Short Percentage of Float Comparison

For the Biotechnology subindustry, NovaBridge Biosciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovaBridge Biosciences Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBridge Biosciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where NovaBridge Biosciences's Short Percentage of Float falls into.


FRA:0VY
24GF Score
NovaBridge Biosciences FRA:0VY
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences Business Description

Other Exchanges NBP:USA
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
24GF Score

Get the complete analysis for FRA:0VY

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.84
Price